vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Safehold Inc. (SAFE). Click either name above to swap in a different company.
Safehold Inc. is the larger business by last-quarter revenue ($97.9M vs $57.3M, roughly 1.7× RHYTHM PHARMACEUTICALS, INC.). Safehold Inc. runs the higher net margin — 28.5% vs -83.0%, a 111.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 6.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.
RYTM vs SAFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $97.9M |
| Net Profit | $-47.5M | $27.9M |
| Gross Margin | 91.6% | 98.6% |
| Operating Margin | -82.2% | 27.4% |
| Net Margin | -83.0% | 28.5% |
| Revenue YoY | 36.9% | 6.5% |
| Net Profit YoY | -9.6% | 7.1% |
| EPS (diluted) | $-0.73 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $97.9M | ||
| Q3 25 | $51.3M | $96.2M | ||
| Q2 25 | $48.5M | $93.8M | ||
| Q1 25 | $32.7M | $97.7M | ||
| Q4 24 | $41.8M | $91.9M | ||
| Q3 24 | $33.3M | $90.7M | ||
| Q2 24 | $29.1M | $89.9M | ||
| Q1 24 | $26.0M | $93.2M |
| Q4 25 | $-47.5M | $27.9M | ||
| Q3 25 | $-52.9M | $29.3M | ||
| Q2 25 | $-46.6M | $27.9M | ||
| Q1 25 | $-49.5M | $29.4M | ||
| Q4 24 | $-43.3M | $26.0M | ||
| Q3 24 | $-43.6M | $19.3M | ||
| Q2 24 | $-32.3M | $29.7M | ||
| Q1 24 | $-141.4M | $30.7M |
| Q4 25 | 91.6% | 98.6% | ||
| Q3 25 | 89.3% | 98.5% | ||
| Q2 25 | 88.6% | 99.1% | ||
| Q1 25 | 88.8% | 98.8% | ||
| Q4 24 | 90.9% | 98.8% | ||
| Q3 24 | 88.5% | 98.8% | ||
| Q2 24 | 89.9% | 98.8% | ||
| Q1 24 | 89.2% | 98.8% |
| Q4 25 | -82.2% | 27.4% | ||
| Q3 25 | -102.6% | 25.9% | ||
| Q2 25 | -93.4% | 25.5% | ||
| Q1 25 | -143.7% | 25.9% | ||
| Q4 24 | -98.6% | 24.6% | ||
| Q3 24 | -132.0% | 17.5% | ||
| Q2 24 | -139.2% | 26.7% | ||
| Q1 24 | -538.7% | 26.4% |
| Q4 25 | -83.0% | 28.5% | ||
| Q3 25 | -103.1% | 30.5% | ||
| Q2 25 | -96.1% | 29.8% | ||
| Q1 25 | -151.4% | 30.1% | ||
| Q4 24 | -103.6% | 28.3% | ||
| Q3 24 | -131.2% | 21.3% | ||
| Q2 24 | -110.9% | 33.0% | ||
| Q1 24 | -544.4% | 33.0% |
| Q4 25 | $-0.73 | $0.38 | ||
| Q3 25 | $-0.82 | $0.41 | ||
| Q2 25 | $-0.75 | $0.39 | ||
| Q1 25 | $-0.81 | $0.41 | ||
| Q4 24 | $-0.71 | $0.36 | ||
| Q3 24 | $-0.73 | $0.27 | ||
| Q2 24 | $-0.55 | $0.42 | ||
| Q1 24 | $-2.35 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $21.7M |
| Total DebtLower is stronger | — | $4.6B |
| Stockholders' EquityBook value | $139.1M | $2.4B |
| Total Assets | $480.2M | $7.2B |
| Debt / EquityLower = less leverage | — | 1.90× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $21.7M | ||
| Q3 25 | $416.1M | $12.1M | ||
| Q2 25 | $291.0M | $13.9M | ||
| Q1 25 | $314.5M | $17.3M | ||
| Q4 24 | $320.6M | $8.3M | ||
| Q3 24 | $298.4M | $15.6M | ||
| Q2 24 | $319.1M | $13.4M | ||
| Q1 24 | $201.2M | $11.3M |
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.4B | ||
| Q1 25 | — | $4.3B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.2B | ||
| Q1 24 | — | $4.1B |
| Q4 25 | $139.1M | $2.4B | ||
| Q3 25 | $148.8M | $2.4B | ||
| Q2 25 | $-11.9M | $2.4B | ||
| Q1 25 | $18.9M | $2.4B | ||
| Q4 24 | $21.7M | $2.3B | ||
| Q3 24 | $11.2M | $2.3B | ||
| Q2 24 | $39.3M | $2.3B | ||
| Q1 24 | $61.6M | $2.3B |
| Q4 25 | $480.2M | $7.2B | ||
| Q3 25 | $506.9M | $7.1B | ||
| Q2 25 | $372.7M | $7.1B | ||
| Q1 25 | $386.7M | $6.9B | ||
| Q4 24 | $392.3M | $6.9B | ||
| Q3 24 | $363.6M | $6.8B | ||
| Q2 24 | $381.8M | $6.8B | ||
| Q1 24 | $258.7M | $6.7B |
| Q4 25 | — | 1.90× | ||
| Q3 25 | — | 1.89× | ||
| Q2 25 | — | 1.87× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.88× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | — | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $47.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $47.8M | ||
| Q3 25 | $-26.6M | $-1.4M | ||
| Q2 25 | $-23.3M | $28.0M | ||
| Q1 25 | $-40.4M | $8.9M | ||
| Q4 24 | $-18.8M | $37.9M | ||
| Q3 24 | $-25.2M | $8.3M | ||
| Q2 24 | $-29.1M | $24.8M | ||
| Q1 24 | $-40.7M | $-3.1M |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | -0.05× | ||
| Q2 25 | — | 1.00× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 0.43× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | -0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
